Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377030368> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4377030368 abstract "Neutralizing antibodies cocktail (casirivimab and imdevimab) has received emergency use authorization recommendation by Food and Drug Administration (FDA) and WHO for mild-to-moderate COVID-19 infection in specific high-risk groups. Antibodies cocktail has shown promising results in preventing progression to severe disease, but the real-world experience is still evolving. Herein, we present a retrospective analysis of 22 patients who were administered the antibodies cocktail between August 2021 and March 2022 at our tertiary care center.We conducted an observational retrospective analysis of clinicoradiological, inflammatory parameters, progression of the disease, and outcome among 22 mild and moderate COVID-19 patients treated with antibodies cocktail.The mean age was 67.7 years (SD ± 18.3) and comprised of 13 males (59%), while 9 were females (40.9%). Nine (40.9%) patients were fully vaccinated with two doses, nine (40.9%) were partially vaccinated with one dose while four patients (18.2%) were unvaccinated, and the rest were unvaccinated. Diabetes and hypertension were the commonest comorbidities; hematological and solid organ malignancies were other comorbidities. Eight patients had radiological opacities consistent with COVID-19 pneumonia and had shown significant regression in four patients after the therapy. None of our patients required supplemental oxygen or progressed to severe acute respiratory distress syndrome. All patients were discharged in a stable condition within 6 days of the therapy.The neutralizing antibodies cocktail has shown encouraging results in our analysis in preventing progression to severe disease in patients with high-risk conditions." @default.
- W4377030368 created "2023-05-19" @default.
- W4377030368 creator A5022163342 @default.
- W4377030368 creator A5025859542 @default.
- W4377030368 creator A5026490909 @default.
- W4377030368 creator A5029244155 @default.
- W4377030368 creator A5042390612 @default.
- W4377030368 creator A5066457080 @default.
- W4377030368 creator A5079316803 @default.
- W4377030368 creator A5087696283 @default.
- W4377030368 date "2023-05-01" @default.
- W4377030368 modified "2023-10-01" @default.
- W4377030368 title "Real-world experience of monoclonal antibodies in mild-to-moderate COVID-19 patients at a tertiary care center" @default.
- W4377030368 cites W2571126731 @default.
- W4377030368 cites W3026318400 @default.
- W4377030368 cites W3034548712 @default.
- W4377030368 cites W3039623205 @default.
- W4377030368 cites W3111431752 @default.
- W4377030368 cites W3133718957 @default.
- W4377030368 cites W3186303569 @default.
- W4377030368 cites W3200700398 @default.
- W4377030368 cites W3211185008 @default.
- W4377030368 cites W3212357575 @default.
- W4377030368 cites W4200366408 @default.
- W4377030368 cites W4225826670 @default.
- W4377030368 cites W4226148899 @default.
- W4377030368 doi "https://doi.org/10.1016/j.mjafi.2023.03.006" @default.
- W4377030368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37360888" @default.
- W4377030368 hasPublicationYear "2023" @default.
- W4377030368 type Work @default.
- W4377030368 citedByCount "0" @default.
- W4377030368 crossrefType "journal-article" @default.
- W4377030368 hasAuthorship W4377030368A5022163342 @default.
- W4377030368 hasAuthorship W4377030368A5025859542 @default.
- W4377030368 hasAuthorship W4377030368A5026490909 @default.
- W4377030368 hasAuthorship W4377030368A5029244155 @default.
- W4377030368 hasAuthorship W4377030368A5042390612 @default.
- W4377030368 hasAuthorship W4377030368A5066457080 @default.
- W4377030368 hasAuthorship W4377030368A5079316803 @default.
- W4377030368 hasAuthorship W4377030368A5087696283 @default.
- W4377030368 hasBestOaLocation W43770303681 @default.
- W4377030368 hasConcept C126322002 @default.
- W4377030368 hasConcept C134018914 @default.
- W4377030368 hasConcept C159654299 @default.
- W4377030368 hasConcept C167135981 @default.
- W4377030368 hasConcept C203014093 @default.
- W4377030368 hasConcept C2777914695 @default.
- W4377030368 hasConcept C2779134260 @default.
- W4377030368 hasConcept C2780630273 @default.
- W4377030368 hasConcept C555293320 @default.
- W4377030368 hasConcept C71924100 @default.
- W4377030368 hasConceptScore W4377030368C126322002 @default.
- W4377030368 hasConceptScore W4377030368C134018914 @default.
- W4377030368 hasConceptScore W4377030368C159654299 @default.
- W4377030368 hasConceptScore W4377030368C167135981 @default.
- W4377030368 hasConceptScore W4377030368C203014093 @default.
- W4377030368 hasConceptScore W4377030368C2777914695 @default.
- W4377030368 hasConceptScore W4377030368C2779134260 @default.
- W4377030368 hasConceptScore W4377030368C2780630273 @default.
- W4377030368 hasConceptScore W4377030368C555293320 @default.
- W4377030368 hasConceptScore W4377030368C71924100 @default.
- W4377030368 hasLocation W43770303681 @default.
- W4377030368 hasLocation W43770303682 @default.
- W4377030368 hasLocation W43770303683 @default.
- W4377030368 hasOpenAccess W4377030368 @default.
- W4377030368 hasPrimaryLocation W43770303681 @default.
- W4377030368 hasRelatedWork W1563850031 @default.
- W4377030368 hasRelatedWork W1877883789 @default.
- W4377030368 hasRelatedWork W2045367862 @default.
- W4377030368 hasRelatedWork W2233866314 @default.
- W4377030368 hasRelatedWork W2316236384 @default.
- W4377030368 hasRelatedWork W2415759662 @default.
- W4377030368 hasRelatedWork W2474749474 @default.
- W4377030368 hasRelatedWork W3036934084 @default.
- W4377030368 hasRelatedWork W3210359220 @default.
- W4377030368 hasRelatedWork W4235434149 @default.
- W4377030368 isParatext "false" @default.
- W4377030368 isRetracted "false" @default.
- W4377030368 workType "article" @default.